Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FP-21399 (Lexigen Pharmaceuticals).

G Poli1, E Vicenzi

  • 1Istituto Scientifico H San Raffaele, DiBit, via Olgettina 58, Milano 20132, Italy. polig@dibit.hsr.it

Idrugs : the Investigational Drugs Journal
|June 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of industrial processing and storage procedures on oxysterols in milk and milk products.

Food & function·2021
Same author

A short-term study of the effects of ozone irrigation in an orthodontic population with fixed appliances.

European journal of paediatric dentistry·2019
Same author

Increased production of 27-hydroxycholesterol in human colorectal cancer advanced stage: Possible contribution to cancer cell survival and infiltration.

Free radical biology & medicine·2019
Same author

Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis.

Journal of endocrinological investigation·2017
Same author

Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Identification of the putative binding pocket of valerenic acid on GABAA receptors using docking studies and site-directed mutagenesis.

British journal of pharmacology·2015
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Lexigen

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Lexigen is developing FP-21399, a novel bis-azo compound, for HIV treatment.
  • Previous studies indicated potential for cellular immune response and antiviral activity.

Purpose of the Study:

  • To evaluate the immunologic and virologic activity of FP-21399 in patients with HIV.
  • To assess the safety and tolerability of FP-21399.

Main Methods:

  • Phase II study: 40 patients failing protease inhibitors received FP-21399 monthly for 48 weeks.
  • Phase I study: 21 patients received intravenous FP-21399 weekly for four weeks in a dose-escalation trial.

Main Results:

  • In Phase I, FP-21399 was well-tolerated. 9/13 patients showed a ≥15% increase in CD4 count.

Related Experiment Videos

  • 2 patients experienced a 1-log (90%) decrease in viral load; 2 achieved undetectable viral loads.
  • FP-21399 interferes with HIV entry by blocking co-receptor use (CXCR4, CCR5) and shows activity against AZT-resistant strains.

    • Conclusions:

    • FP-21399 demonstrates promising immunologic and virologic effects in HIV patients.
    • The compound's mechanism of action and favorable toxicity profile warrant further investigation.